

## **PUBLIKATIONSLISTE 1993 - 2018**

### **ORIGINALARBEITEN**

1. Pharmacokinetics of tenoxicam in patients with impaired renal function. F.F. Horber, E. Weidekamm, T.W. Guentert, P. Heizmann, C. Descoedres, F.J. Frey. Eur J Clin Pharmacol 1986;29:697-701.
2. Thigh muscle mass and function in patients treated with glucocorticoids. F.F. Horber, J.R. Scheidegger, B.E. Gruenig, F.J. Frey. Eur J Clin Invest 1985;15:302-7.
3. Hypertension as related to renal function in diabetes mellitus. F.C. Reubi, K.A. Franz, F. Horber. Hypertension 1985;7 (Suppl 2):21-8.
4. Evidence that prednisone-induced myopathy is reversed by physical training. F.F. Horber, J.R. Scheidegger, B.E. Gruenig, F.J. Frey. J Clin Endocrinol Metab 1985;61:83-88. Yearbook of Endocrinology 1986;257.
5. Pharmacokinetics of carumonam in patients with renal insufficiency. F.F. Horber, H.J. Egger, E. Weidekamm, U.C. Dubach, F.J. Frey, P.J. Probst, K. Stoeckel. Antimicrob Agents Chemother 1986;29:116-21.
6. The effect of liver function on the metabolism of prednisone and prednisolone in humans. E. Renner, F.F. Horber, G. Jost, B.M. Frey, F.J. Frey. Gastroenterology 1986;90:819-28.
7. Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. F.F. Horber, F.J. Frey, C. Descoedres, A.T. Murray, F.C. Reubi. Antimicrob Agents Chemother 1986;29:614-9.
8. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. F.F. Horber, R.M. Zuercher, H. Herren, M.A. Crivelli, G. Robotti, F.J. Frey. Am J Clin Nutr 1986;43:758-69.
9. Altered skeletal muscle ultrastructure in renal transplant patients on prednisone. F.F. Horber, H. Hoppeler, D. Herren, H. Claassen, H. Howald, C.H. Gerber, F.J. Frey. Kid Int 1986;30:411-6.
10. Overestimation of renal function in glucocorticosteroid treated patients. F.F. Horber, J.R. Scheidegger, F.J. Frey. Eur J Clin Pharmacol 1985;28:537-541. Yearbook of Drug Therapy 1987;41-3.
11. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. F.J. Frey, A. Schnetzer, F.F. Horber, B.M. Frey. Transplantation 1987;43:494-8.
12. Distinct distribution of periarticular erosions of the hand skeleton in dialysis patients. B. Gerber, F.F. Horber, G. Robotti, J.R. Scheidegger, F.J. Frey. Am J Nephrology 1987;7:459-63.
13. Impact of physical training on the ultrastructure of midhigh-muscle in normal subjects and in patients treated with glucocorticoids. F.F. Horber, H. Hoppeler, J.R. Scheidegger, B.E. Gruenig, H. Howald, F.J. Frey. J Clin Invest 1987;79:1181-1190. Yearbook of Sports Medicine 1988;102.
14. Through levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. F.J. Frey, F.F. Horber, B. M. Frey. Clin Pharm Ther 1988;43:55-62.
15. Anaesthesia with halothane and nitrous oxide alters protein and amino acid metabolism in dogs. F.F. Horber, S. Kraye, K. Rehder, M.W. Haymond. Anaesthesiology 1988;69:319-26.
16. Altered metabolism and decreased efficacy of prednisolone and prednisone in patients with hyperthyroidism. F.J. Frey, F.F. Horber, B.M. Frey. Clin Pharm Ther 1988;44:510-21.
17. High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance. F.F. Horber, O. Maurer, P.J. Probst, E. Heizmann, F.J. Frey. Eur J Clin Pharmacol 1989;36:389-93.
18. Plasma reciprocal pool specific activity predicts that of intracellular free leucine SA for protein synthesis. F.F. Horber, C.M. Horber-Feyder, S. Kraye, W.F. Schwenk, M.W. Haymond. Am J Physiol 1989;257:E 385-99.
19. Impaired liver function in stable renal allograft recipients. F.J. Frey, H.J. Schaad, E.L. Renner, F.F. Horber, B.M. Frey, R. Preisig. Hepatology 1989;9:606-13.

20. Determination of plasma concentrations and <sup>3</sup>H-specific activity of phenylalanine in plasma using high-performance liquid chromatography. L. Lecavalier, F.F. Horber, M.W. Haymond J Chromatography (Biomed Appl) 1989;491:410-7.
21. Contribution of insulin resistance to catabolic effect of prednisone on leucine metabolism in humans. T.N. Zimmermann, F.F. Horber, N. Rodriguez, W.F. Schwenk, M.W. Haymond. Diabetes 1989;38:1238-44.
22. Effects of thyroid dysfunction on thigh muscle efficiency. R.M. Zuercher, F.F. Horber, B.E. Gruenig, F.J. Frey. J Clin Endocrinol Metab 1989;69:1082-6.
23. Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. B. Beaufriere, F.F. Horber, W.F. Schwenk, H.M. Marsh, D. Matthews, J.E. Gerich, M.W. Haymond. Am J Physiol 1989;257:E 712-21.
24. Determination of leucine and  $\alpha$ -ketoisocaproic acid concentrations and specific activity in plasma and leucine specific activities in proteins using high-performance liquid chromatography. F.F. Horber, J.C. Kahl, B.A. Krom, M.W. Haymond. J Chromatography (Biomed Appl) 1989;495:81-94.
25. Isoflurane and whole body leucine, glucose and fatty acid metabolism in dogs. F.F. Horber, S. Kraye, J. Miles, P. Cryer, K. Rehder, M.W. Haymond. Anaesthesiology 1990;73:82-92.
26. Disposition kinetics of moclobemide, a new Mao-A inhibitor in subjects with impaired renal function. M.P. Schoerlin, F.F. Horber, F.J. Frey, M. Mayersohn. J Clin Pharmacol 1990;30:272-84.
27. Preservation of body composition in renal transplant patients by cyclosporine as opposed to prednisone. R.M. Zuercher, S. Koehn, G. Thiel, F.J. Frey, F.F. Horber. Transplantation 1990;50:159-62.
28. Human growth hormone prevents the protein catabolic effects of prednisone in humans. F.F. Horber, M.W. Haymond. J Clin Invest 1990;86:265-72. JAMA 1990;264:1650, From the National Institute of Health.
29. Orthotope Lebertransplantation am Inselspital. J.P. Lerut, Ph. Gertsch, P.J. Luder, A. Zimmermann, E.A. Dijkhuis, H.U. Rothen, B. Ott, U. Nydegger, F. Horber, H.U. Fisch, J. Scheidegger, R. Preisig, L.H. Blumgart. Helv Chir Acta 1991;57:865-80.
30. Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. F.F. Horber, H.M. Marsh, M.W. Haymond. Diabetes 1991;40:141-9.
31. Impact of dialysis modality on body composition in patients with end stage renal disease. H. Saxenhofer, J. Scheidegger, Ph. Jaeger, C. Descoedres, F.F. Horber. Clin Nephrology 1992;38:219-36.
32. Impact of hydration status on body composition as measured by dual energy X-ray absorptiometry (DXA) in normal volunteers and patients on hemodialysis. F.F. Horber, F. Thomi, J.P. Casez, J. Fontelle, Ph. Jaeger. Br J of Radiology 1992;65:895-900.
33. Low dose rhIGF-I fails to affect protein anabolism but inhibits islet cell secretion in humans. N. Mauras, F.F. Horber, M.W. Haymond. J Clin Endocrinol Metab 1992;75:1192-7.
34. Meal stimulation of albumin synthesis: a significant contributor to whole body protein synthesis in humans. P. De Feo, F.F. Horber, M.W. Haymond. Am J. Physiol 1992;263:E794-9.
35. Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Y. Allemann, F.F. Horber, M. Colombo, S. Shaw, P. Ferrari, Ph. Jaeger, P. Weidmann. Lancet 1993;341:327-31.
36. Impact of time-interval after transplantation and therapy with fibrates on serum cholesterol levels in renal transplant patients. J.A. Fuhrer, A. Montandon, C. Descoedres, Ph. Jaeger, F.F. Horber. Clin Nephrology 1993;39:265-71.
37. The effect of human growth hormone and insulin like growth factor I on whole-body leucine and estimates of protein metabolism. M.W. Haymond, F.F. Horber, P. De-Feo, S.E. Kahn, N. Mauras. Horm Res 1993;40:92-4.
38. Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans. S. Kahn, F.F. Horber, R.L. Prigeon, M.W. Haymond, D. Porte Jr.. Diabetes 1993;42:1082-5.

39. Zur Treffsicherheit der intravenösen digitalen Subtraktionsangiographie bezüglich Nierenarterien bei Hypertonikern. M.P. Lüthi, P. Vock, F.F. Horber. Schweiz Med Rundschau (Praxis) 1993;82:927-33.
40. Altered body composition and fuel metabolism in stable kidney transplantat patients on immunosuppressive monotherapy with cyclosporin A. R.L. Matthieu, J.P. Casez, A. Montandon, Ph. Jaeger, F.F. Horber. Eur J Clin Invest 1994;24:195-200.
41. Changes in bone mass early after kidney transplantation. F.F. Horber, J.P. Casez, U. Steiger, A. Czerniak, A. Montandon, Ph. Jaeger. J Bone Mineral Research 1994;9:1-9.
42. Kann sich die Qualität eines kleinen Lebertransplantations-Programmes mit dem internationalen Standard messen? Resultate am Inselspital Bern. Ch.A. Seiler, E.L. Renner, F. Horber, H. Rieder, J. Reichen, A. Czerniak. Schweiz Med Wochenschr 1994;124:2123-30.
43. Altered parathyroid gland function in severely immunocompromised patients infected with human immunodeficiency virus. Ph. Jaeger, S. Otto, R.F. Speck, L. Villiger, F.F. Horber, J.P. Casez, R. Takkinen. J Clin Endocrinol Metab 1994;79:1701-5.
44. Body composition and fuel metabolism after kidney grafting. U. Steiger, K. Lippuner, E.X. Jensen, A. Montandon, Ph. Jaeger, F.F. Horber. Eur J Clin Invest 1995;25:809-16.
45. Impact of chronic cigarette smoking on body composition and fuel metabolism. E.X. Jensen, Ch. Fusch, Ph. Jaeger, E. Peheim, F.F. Horber. J Clin Endocrinol Metab 1995;80:2181-5.
46. Ultrastructural modification of human skeletal muscle tissue with 6-month moderate-intensity training. E. Suter, H. Hoppeler, H. Claassen, R. Billeter, U. Aebi, F. Horber, P. Jaeger, B. Marti. Int J Sports Med 1995;16:160-6.
47. Evidence for preservation of cortical bone mineral density in patients on continuous ambulatory peritoneal dialysis (CAPD). J.J. Mottet, F.F. Horber, J.P. Casez, C. Descoedres, Ph. Jaeger. J Bone Mineral Research 1996;11:96-104.
48. Six month overnight dialysis with 1% amino acid solution decreases fat mass in patients with terminal renal failure. O. Maurer, H. Saxenhofer, J.P. Casez, Ph. Jaeger, C. Descoedres, F.F. Horber. Clin Nephrol 1996;45:303-9.
49. Effect of regular physical training on age-associated alteration of body composition in men. F.F. Horber, S.A. Kohler, K. Lippuner, P. Jaeger. Eur J Clin Invest 1996;26:279-85.
50. Differential effect of sex and age on bone mass, body composition and fuel metabolism in humans. F.F. Horber, B. Gruber, F. Thomi, E.X. Jensen, Ph. Jaeger. Nutrition 1997;13:524-34.
51. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. W. Hänggi, K. Lippuner, Ph. Jaeger, M.H. Birkhäuser, F.F. Horber. Clin Endocrinol (Oxf) 1998;48(6):691-9.
52. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. K. Lippuner, J.P. Casez, F.F. Horber, P. Jaeger. J Clin Endocrinol Metab 1998;83:3795-802.
53. Swedish adjustable gastric band (SAGB)-distal gastric bypass: a new variant of an old technique in the treatment of superobesity and failed band restriction. R. Steffen, F. Horber, P. Hauri. Obes Surg 1999;9:171-6.
54. Is bariatric surgery worth its cost? P. Hauri, F.F. Horber, P. Sendi. Obes Surg 1999;9:480-3.
55. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized placebo controlled double blind study. K. Läderach-Hoffmann, C. Graf, F. Horber, K. Lippuner. Int J Eat Disord 1999;26:231-44.
56. Treatment of morbid obesity with the Swedish Adjustable Gastric Band (SAGB): Complication rate during a 12-month follow-up period. Ph. Hauri, R. Steffen, Th. Ricklin, H.J. Riedtmann, P. Sendi, F.F. Horber. Surgery 2000;127:484-8.

57. Einfluss eines kontrollierten Rekonditionstrainings auf Leistungsentwicklung und Psyche bei Patienten nach aortokoronarer Bypassoperation. G. Haeberli, F.F. Horber. Schweiz Med Rundschau (Praxis) 2000;89:1685-93.
58. Conservative management of intragastric migration of a Swedish Adjustable Gastric Band: 4 cases of endoscopic retrieval. R. Baldinger, R. Muench, R. Steffen, Th.P. Ricklin, H.J. Riedtmann, F.F. Horber. Gastrointest Endosc 2001;53:98-101.
59. Diät und Medikamente in der Behandlung der Adipositas. N. Potoczna, R. Steffen, Th. Ricklin, G. Picc, F.F. Horber. Aktuelle Medizin 2001;14:7-9.
60. Aktuelle Entwicklungen in der Uebergewichtschirurgie. R. Steffen, G. Picc, F.F. Horber. Aktuelle Medizin 2001; 14:10-2.
61. Salvage of Swedish Adjustable Gastric Band (SAGB) after explantation of an infected port. R. Baldinger, R. Steffen, Th. P. Ricklin, F.F. Horber. Surgery 2002;131:350-1.
62. Impact of orlistat therapy on weight reduction in morbid obese patients after implantation of a Swedish Adjustable Gastric Band (SAGB). I. Zoss, G. Picc, F.F. Horber. Obes Surg 2002;12:113-7.
63. Modeling the impact of adjustable gastric banding on survival in patients with morbid obesity. P. Sendi, A.J. Palmer, Ph. Hauri, B.A. Craig, F.F. Horber. Obes Res 2002;10:291-5.
64. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. J.P. Casez, K. Lippuner, F.F. Horber, A. Montandon, Ph. Jaeger. Nephrol Dial Transplant 2002;17:1318-26.
65. Anti-Xa-Activity in obese patients after doubled standard dose of nadroparin for prophylaxis. M. Heizmann, G. Baerlocher, F. Steinemann, F. Horber, W.A. Wuillemin. Thrombosis Research 2002;15:179-85.
66. Binge eating as a major phenotype of melanocortin-4 receptor gene mutations. R. Branson, N. Potoczna, J.G. Kral, K.U. Lenten, M.R. Hoehe, F.F. Horber. N Engl J Med 2003;348:1096-103.
67. Laparoscopic adjustable gastric banding with duodenal switch. M. Gagner, R. Steffen, L. Biertho, F. Horber. Obes Surg 2003;13:444-9.
68. Laparoscopic Adjustable gastric banding: a five-year prospective study. R. Steffen, L. Biertho, Th. Ricklin, G. Picc, F.F. Horber. Obes Surg 2003;13:404-11.
69. Effect of intermediate term weight loss on serum leptin levels and body composition. D. Infanger, R. Baldinger, R. Branson, Th. Barbier, R. Steffen, F.F. Horber. Obes Surg 2003;13:879-88.
70. Laparoscopic gastric bypass versus laparoscopic adjustable gastric banding: a comparative study of 1200 cases. L. Biertho, R. Steffen, T. Ricklin, F.F. Horber, A. Pomp, W.B. Inabnet, D. Herren, M. Gagner. J Am College of Surgeons 2003;197:536-44; Discussion 544-5.
71. Laparoscopic Roux-en-Y Gastric Bypass, but not rebanding, should be proposed as rescue procedure for patients with failed laparoscopic gastric banding. M. Weber, M. Müller, J.M. Michel, R. Belal, F. Horber, R. Hauser, P.A. Clavien. Ann Surgery 2003;238:827-33;Discussion 833-4.
72. Übergewicht: Wann hilft (nur noch) die Chirurgie? N. Potoczna, G. Picc, T. Ricklin, R. Steffen, F.F. Horber. Kardiovaskuläre Medizin 2004;7:206-13.
73. G-protein polymorphisms do not predict weight loss and improvement of hypertension in severely obese patients. N. Potoczna, M. Wertli, R. Steffen, T. Ricklin, K-U. Lenten, F.F. Horber. J Gastrointest Surg 2004;8:862-8.
74. Gene variants and binge eating as predictors of comorbidity and outcome of treatment of severe obesity. N. Potoczna, R. Branson, J.G. Kral, G. Picc, R. Steffen, T. Ricklin, M.R. Hoehe, K-U. Lenten, F.F. Horber. J Gastrointest Surg 2004;8:971-82.
75. Laparoscopic Roux-en-Y gastric bypass is more efficient than laparoscopic gastric banding. M. Weber, M.K. Müller, T. Bucher, S. Wildi, D. Dindo, F. Horber, R. Hauser, P-A. Clavien. Ann Surgery 2004;240: 975-82.

76. Management of failed adjustable gastric banding. L. Biertho, R. Steffen, R. Branson, N. Potoczna, T. Ricklin, G. Piec, F.F. Horber. *Surgery* 2005;137:33-41.
77. Salvage of gastric restriction following internal staple line dehiscence after vertical banded gastroplasty by insertion of an adjustable gastric band. M. Wenger, G. Piec, R. Branson, N. Potoczna, F.F. Horber, R. Steffen. *Obesity Surgery* 2005;15:216-22.
78. Analysis of sequence variability in *CART* gene in relation to obesity in a Caucasian population. A. Guérardel, M. Barat-Houari, F. Vasseur, C. Dina, V. Vatin, K. Clément, D. Eberlé, V. Vasseur-Delannoy, C. Bell, P. Galan, S. Hercberg, N. Helbecque, N. Potoczna, F.F. Horber, P. Boutin, P. Froguel. *BMC Genet* 2005;6:19. doi:10.1186/1471-2156-6-19.
79. Impact of age, sex and body mass index on treatment outcomes at four years after gastric banding. R. Branson, N. Potoczna, R. Brunote, G. Piec, T. Ricklin, R. Steffen, F.F. Horber. *Obes Surg* 2005;15:834-42.
80. Health-related quality of life in patients with class II and class III obesity. P. Sendi, R. Brunnotte, N. Potoczna, R. Branson, F.F. Horber. *Obes Surg* 2005;15:1070-6.
81. Infrequent non synonymous polymorphisms in Melanocortin 4 receptor protect against obesity: the two faces of a Janus obesity gene. F. Stutzmann, V. Vatin, S. Cauchi, C. Lecoeu, A. Morandi, D. Serre, B. Heude, B. Jouret, C. Le Stunff, J. Ruiz, N. Potoczna, O. Landt, P. Tounian, C.L. Marchal, R. Buzzetti, L. Pinelli, auteur Desir 3, F. Horber, P. Bougnères, P. Froguel, D. Meyre. *Hum Mol Genet.* 1;16 (15):1837-44.
82. Variation in FTO contributes to childhood obesity and severe adult obesity. Dina C, Meyre D, Gallina S, Durand, Korner A, Jacobson P, Carlsson LM, Kiess W, Vatin V, Lecouer C, Delplanque J, Vaillant E, Pattou F, Ruiz J, Weill J, Levy-Marchal C, Horber F, Potoczna N, Hercberg S, Le Stunff C, Bougnères P, Kovacs P, Marre M, Balkau B, Cauchi S, Chevre JC, Froguel P. *Nature Genetics* 2007, 39(6):324-26.
83. Effects of TCF7L2 Polymorphisms on Obesity in European Populations. Cauchi S, Choquet H, Gutiérrez-Aguilar R, Capel F, Grau K, Proença C, Dina C, Duval A, Balkau B, Marre M, Potoczna N, Langin D, Horber F, Sørensen TI, Charpentier G, Meyre D, Froguel P. *Obesity (Silver Spring)*. 2008,16(2):476-82
84. Severe Recurrent Hypoglycemia after Gastric Bypass Surgery" Obesity Surgery K. Z'graggen, A. Guweidhi, R. Steffen, N. Potoczna, R. Biral, F. Walther, P. Komminoth, F. Horber. 18: 981-988
85. Bowel Habits After Bariatric Surgery. Potoczna N, Harfmann S, Steffen R, Briggs R, Bieri N, Horber FF. *Obesity Surgery* 2008 18:1287-1196.
86. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Benzinou M, Chèvre JC, Ward KJ, Lecoeur C, Dina C, Lobbens S, Durand E, Vatin V, Delplanque J, Horber FF, Potoczna N, Heude B, Balkau B, Blakemore A, Jorgensen T, Hansen T, Pedersen O, Boutin P, Meyre D and Froguel P. *Human Molecular Genetics*, 2008 Jul 1;17(13):1916-21. Epub 2008 Mar 28.
87. The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies. Cauchi S, Nead K, Choquet H, Horber FF, Potoczna N, Balkau B, Marre M, Charpentier G, Froguel P and Meyre D. *BMC Medical Genetics* 2008, 9:45
88. Prevalence of MC4R deficiency in European population and their age-dependant penetrance in multi-generational pedigrees. Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J, Balkau B, Potoczna N, Horber FF, O'Rahilly S, Farooqi IS, Froguel P and Meyre D. *Diabetes*, 2008 Sep;57(9):2511-8.
89. Common non-synonymous variants in PCSK1 confer risk of obesity in Europeans. Michael Benzinou, John W.M. Creemers, Helene Choquet, Stephane Lobbens, Christian Dina, Emmanuelle Durand, Audrey Guerardel, Philippe Boutin, Beatrice Jouret, Barbara Heude, Beverley Balkau, Jean Tichet, Michel Marre, Natascha Potoczna, Fritz Horber, Catherine Le-Stunff<sup>1</sup>, Sebastien Czernichow, Anelli Sandbaek, Torsten Lauritzen, Knut Borch-Johnsen, Wieland Kiess, Antje Körner, Peter Kovacs, Peter Jacobson, Lena MS Carlsson, Andrew Walley, Torben Hansen, Oluf Pedersen, David Meyre and Philippe Froguel. *Nature Genetics*, 2008 Aug; 40(8):943-5. .
90. Successful Multi-Intervention Treatment of Severe Obesity: A 7-year Prospective Study with 96% Follow-up. Steffen R, Potoczna N, Bieri N and Horber FF. *Obesity Surgery*. 2009 Jan; 19(1):3-12.

91. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Meyre D, Delplanque J, Chèvre JC, Lecoœur C, Lobbens S, Gallina S, Durand E, Vatin V, Degraeve F, Proença C, Gaget S, Körner A, Kovacs P, Kiess W, Tichet J, Marre M, Hartikainen AL, Horber F, Potoczna N, Hercberg S, Levy-Marchal C, Pattou F, Heude B, Tauber M, McCarthy MI, Blakemore AI, Montpetit A, Polychronakos C, Weill J, Coin LJ, Ashere J, Elliott P, Järvelin MR, Visvikis-Siest S, Balkau B, Sladek R, Balding D, Walley A, Dia C, Froguel P. *Nature Genetics*. 2009 Feb;41(2):157-9.
92. Common genetic variation near MC4R is associated with eating behaviour patterns in European populations. Stutzmann F, Cauchi S, Durand E, Calvacanti-Proença C, Pigeyre M, Hartikainen AL, Sovio U, Tichet J, Marre M, Weill J, Balkau B, Potoczna N, Laitinen J, Elliott P, Järvelin MR, Horber F, Meyre D, Froguel P. *Int J Obes (Lond)*. 2009 Mar;33(3):378-8.
93. The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49'279 subjects. Choquet H, Cavalcanti-Proença C, Lecoœur C, Dina C, Cauchi S, Vaxillaire M, Hadjadj S, Horber F, Potoczna N, Charpentier G, Ruiz J, Hercberg S, Maimaitiming S, Roussel R, Boenhneke M, Jackson AU, Patsch W, Krempler F, Voight BF, Altshuler D, Groop L, Thorleifsson G, Steinthorsdottir V, Stefansson K, Balkau B, Froguel P, Meyre D. *Hum Mol Genet*. 2009 Jul 1;18(13):2495-501.
94. A genetic variant in HK1 is associated with pro-anemic state and HbA1c but not other glycemic control related traits. Bonnefond A, Vaxillaire M, Labrune Y, Lecoœur C, Chèvre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, Riveline JP, Hadjadj S, Gallois Y, Czernichow S, Hercberg S, Kaakinen M, Wiesner S, Charpentier G, Lévy-Marchal C, Elliott P, Jarvelin MR, Horber F, Dina C, Pedersen O, Sladek R, Meyre D, Froguel P. *Diabetes*. 2009 Nov;58(11):2687-97.
95. Prevalence of loss-of-function FTO mutations in lean and obese individuals. Meyre D, Proulx K, Kawagoe-Takaki H, Vatin V, Gutiérrez-Aguilar R, Lyon D, Ma M, Choquet H, Horber F, Van Hul W, Van Gaal L, Balkau B, Visvikis-Siest S, Pattou F, Farooqi IS, Saudek V, O'Rahilly S, Froguel P, Sedgwick B, Yeo GS. *Diabetes*. 2010 Jan;59(1):311-8.
96. Impaired lipid sensor GPR120 contributes to both Mouse and Human obesity. Atsuhiko Ichimura, Akira Hirasawa, Odile Poulain-Godefroy, Amélie Bonnefond, Takafumi Hara, Loïc Yengo, Ikuo Kimura, Audrey Leloire, Ning Liu, Keiko Iida, Hélène Choquet, Philippe Besnard, Cécile Lecoœur, Sidonie Vivequin, Kumiko Ayukawa, Masato Takeuchi, Maithé Tauber, Claudio Maffei, Anita Morandi, Raffaella Buzzetti, Paul Elliott, Marjo-Riitta Jarvelin, Wim Van Hui, Luc Van Gaal, Fritz Horber, Beverley Balkau, Claire Lévy-Marchal, Konstantinos Rouskas, Anastasia Kouvasi, François Pattou, David Meyre, Taka-aki Koshimizu, Isabelle Wolowczuk, Gozoh Tsujimoto, Philippe Froguel. *Nature*. 2012 Feb 19;483(7389):350-4.
97. Heterozygous Mutations Causing Partial Prohormone Convertase 1 Deficiency Contribute to Human Obesity. Creemers JW, Choquet H, Stijnen P, Vatin V, Pigeyre M, Beckers S, Meulemans S, Than ME, Yengo L, Tauber M, Balkau B, Elliott P, Jarvelin MR, Van Hul W, Van Gaal L, Horber F, Pattou F, Froguel P, Meyre D. *Diabetes*. 2012 Feb;61(2):383-90.
98. Common variants near BDNF and SH2B1 show nominal evidence of association with snacking behaviour in European populations. Robiou-du-Pont S, Yengo L, Vaillant E, Lobbens S, Durand E, Horber F, Lantieri O, Marre M, Balkau B, Froguel P, Meyre D. *J Mol Med (Berl)* 2013 Sep;91(9):1109-15.
99. Eating Behavior, Low-Frequency Functional Mutations in the Melanocortin-4 Receptor (*MC4R*) Gene, and Outcomes of Bariatric Operations: A Six-Year Prospective Study. Amélie Bonnefond, Ramsi Keller, David Meyre, Fanny Stutzmann, Dorothée Thuillier, Dimitre G. Stefanov, Philippe Froguel, Fritz F. Horber, John G. Kral. *Diabetes Care* 2016 Aug;39(8):1384-92.
100. Reversal of Long-Term Weight Regain after Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision . A Prospective Study. Fritz. F. Horber, R. Steffen. *Obesity Surgery* 2020 in press 21. Juli

#### CASE REPORTS/LETTER TO THE EDITOR

101. Die metabolische Bedrohung nach Rekonstruktion der arteriellen Strombahn bei schwerster Muskelischemie. B. Nachbur, F. Horber, K.H. Gaenger, C. Descoeurdes. *Helv Chir Acta* 1983;50:749-51. Impaired renal function and hypercalcaemia associated with etretinate. F.F. Horber, A. Zimmermann, F.J. Frey *Lancet* 1984;2:1093.
102. Renal tubular acidosis, a side effect of treatment with pentavalent antimony. F.F. Horber, J. Lerut, Ph. Jaeger. *Clin Nephrology* 1991;36:213.

103. Transitory alexia without agraphia in a HIV-positive patient suffering from toxoplasma-encephalitis. Ch. Lüscher, F. F. Horber, Ph. Jaeger. Eur Neurology 1992;32:26-7.
104. Toxizität einer organischen Germanium-Verbindung: Deletäre Folgen eines „Naturheilmittels“. J. Raisin, B. Hess, M. Blatter, A. Zimmermann, C. Descoedres, F.F. Horber, Ph. Jaeger. Schweiz Med Wochenschrift 1992;122:11-3.
105. Ernährungstherapie bei enteraler Hyperoxalurie. F.F. Horber, G. Pedrazzini, B. Hess, M. Gurtner. Aktuelle Ernährungsmedizin 1992;17:14-7.
106. Anti A/B Histobloodgroup IGM/G/A serum quantities to monitor outcome of kidney transplantation. A. Sandberg-Tschopp, F. Horber, J. Lerut, R. Rieben, U.E. Nydegger. Transfus Sci 1992;13:455-6.
107. Laparoscopic cholecystectomy in a patient on continuous ambulatory peritoneal dialysis. R. Speck, A. Glättli, A. Czerniak, D. Uehlinger, F.F. Horber. Clin Nephrology 1992;38:238.
108. Visceral leishmaniasis after orthotopic liver transplantation: Impact of persistent splenomegaly. F.F. Horber, J. Lerut, J. Reichen, A. Zimmerman, Ph. Jaeger, R. Malinverni. Transplant Int 1993;6:55-7.
109. Enteropathy-associated T-cell lymphoma in a renal transplant patient with evidence of Epstein-Barr virus involvement. B. Borisch, I. Hennig, F. Horber, K. Bürki, J. Laissue. Virchows Arch A Pathol Anat Histopathol 1992;421:443-7.
110. Tubulointerstitial nephropathy persisting 20 months after discontinuation of chronic intake of germanium lactae citrate. B. Hess, J. Raisin, A. Zimmermann, F. Horber, S. Bajo, A. Wytttenbach, Ph. Jaeger. Am J Nephrol 1993;21:548-52.
111. Laparoscopic intraperitoneal drainage of lymphocele after renal transplantation. Ch. Seiler, F. Horber, A. Czerniak. Nephrol Dial Transplant 1994;9:185-90.
112. Elektrolytstörungen und Bewusstseinsverlust eines 63-jährigen Alkoholikers. F.F. Horber, H.J. Altermatt Schweiz Med Rundschau (Praxis) 1996;85:559-66.
113. Antibody studies in a patient with acute thrombocytopenia following infusion of plasma containing anti-PI (A 1). S. Brunner-Bolliger, V. Kiefel, F.F. Horber, U.E. Nydegger, P. Berchtold. Am J Hematol 1997;56:119-21.
114. Binge eating as a major phenotype of melanocortin-4 receptor gene mutations. The authors reply: JG. Kral, K.U. Lentens, F.F. Horber. N Engl J Med 2003;349:608-9.

## REVIEWS

115. Behandlung der Osteoporose. F.F. Horber. Pharma-Kritik 1984;6:13-8.
116. Metabolic disorders in acute limb ischemia. B. Nachbur, F. Horber, S. Sigrist. Proceedings of the Symposium on Vascular Surgical Emergencies 1986;111-25.
117. Anabolika und Sport. F.F. Horber. Schweiz Med Wochenschrift 1990;120:383-7.
118. Muskuläre Probleme infolge von Medikamenten. F.F. Horber, P. Ritzmann. Pharma-Kritik 1991;13:9-12.
119. The effects of human growth hormone and prednisone on whole body estimates of protein metabolism. M.W. Haymond, F.F. Horber. Horm Res 1992;38 (Suppl 2):44-6.
120. Human growth hormone but not insulin like growth factor-I positively effect whole body estimates of protein metabolism. N. Mauras, F.F. Horber, M.W. Haymond. Horm Res 1992;38 (Suppl 1):73-5.
121. Nieren- und Lebertransplantation in Bern, eigene Resultate. F. Horber, A. Czerniak. Inselbote 1992;26(3):64-6.
122. Personalumfrage 1992. U. Bürgi, F.F. Horber, K. Franz, M. Müller, B. Schütz, A. Sterchi, J.P. Habegger, H.J. Ryssel. Inselbote 1993;3:37-45.
123. Hyperlipidämie nach Nierentransplantation. F. Horber. SVERB Bulletin-ASDD 1993;S1:7-8.

124. Consensus über die Behandlung der Adipositas in der Schweiz 1999. Golay A für die Consensusgruppe; F.F. Horber für die Bariatrische Chirurgie. Schweiz Med Wochenschr 1999; 49 Supp 114:3S-20S.
125. The place of liver transplantation in the treatment of hemorrhagic complications of portal hypertension. A. Czerniak, W. Schweizer, Ch. Seiler, F. F. Horber. Austria Chir Acta 1993;25:169-171.
126. Magenbanding. Steffen, F.F. Horber. Aktuelle Medizin 1995;1:17-20.
127. Abklärungsprocedere bei Nierenarterienstenose. P. Wagdi, F. Horber. Schweiz Med Rundschau (Praxis) 2000;20:133-42.
128. Swedish Adjustable Gastric Band (SAGB) in combination with antiobesity drug therapy. G. Piec, R. Baldinger, R. Steffen, Th. Ricklin, F.F. Horber. Digestive Surgery 2000;17:556-7.
129. Preoperative Evaluation and selection of patients for bariatric surgery. R. Baldinger, G. Piec, R. Steffen, Th.P. Ricklin F.F. Horber. Digestive Surgery 2000;17:558-9.
130. Gesundheitliche Folgen des Fast Food. N. Potoczna, F. Horber. Fast Food und Gesundheit. Schweizerische Gesellschaft für Ernährung, Bern, 2005;85:25-32.
131. Flaws in methods of evidence-based medicine may adversely affect public health directives. J.G. Kral, J.B. Dixon, F.F. Horber, S. Rossner, S. Stiles, S. Torgerson. Surgery 2005;137:279-84.
132. Surgical procedures for severely obese patients: impact and long-term results. N. Potoczna, R. Steffen, F.F. Horber. Internist 2006;47:150-8.
133. Inter-disciplinary European guidelines on surgery of severe obesity. Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finan N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. Int J Obes (Lond). 2007 Apr;31(4):569-77. Epub 2007 Feb 27.
134. Bariatric Scientific Collaborative Group Expert Panel. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finan N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. Obes Surg. 2007 Feb;17(2):260-70.
135. Adipositas therapie- facts and fiction!. F. Horber, R. Steffen, N. Potoczna. Adipositas 2009, 149-157.
136. Langzeitergebnisse der bariatrischen Chirurgie bei morbidem Adipositas. R. Steffen, N. Potoczna, D. Steiger, F. Horber, Adipositas 2009, 201-209
137. Komplikationen in der Bariatrie – „red flags“ für die Praxis. F.F.Horber, R. Steffen, Th. Frick, N. Potoczna, S. Herren. Schweiz. Zeitschrift für Ernährungsmedizin 2011;4:23-29

#### **VIDEO KONFERENZEN**

138. Laparoscopic adjustable gastric banding with duodenal switch biliopancreatic bypass. R. Steffen, F.F. Horber, M. Gagner. American College of Surgeons Video Library.